ClinicalTrials.gg
CompletedNCT02968914Updated Jul 5, 2019Results posted

Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers

A Phase 1 interventional study of Benralizumab and Benralizumab in Asthma and Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 2 sites in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-05.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
14th of 39
180 · median 128
Started
2017
with 3 others
Phase 1
3 of 39
none open now
Registered
19th of 39
by date
Lead sponsor
24 of 39
AstraZeneca

Among the 39 studies testing benralizumab in Asthma, this one is the 14th largest by enrollment, is one of 4 that started in 2017, is one of 3 in phase 1, and was the 19th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

An open-label, single dose Pharmacokinetic (PK) comparability study to demonstrate comparable drug exposure following Subcutaneous benralizumab administration by using accessorized pre-filled syringe (APFS) or autoinjector (AI) devices.

Read the detailed description

A study of descriptive comparison of benralizumab PK by weight and injection site.

This study will be a multicenter, randomized, open-label, parallel group Phase 1 study designed to compare benralizumab PK exposure in healthy subjects following single subcutaneous (SC) administration of fixed 30 mg dose of benralizumab by using APFS and single-use AI. Eligible subjects will be healthy subjects aged 18 to 55 years, with a body weight of 55 to 100 kg and a body mass index of 18 to 29.9 kg/m2 . A total of 180 subjects will be randomized. Randomization will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg), and within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS or AI) with injection site (upper arm, abdomen or thigh), presented in Table 1. This study will be performed at 2 study centers.

03

Conditions studied

  • Asthma
  • Chronic Obstructive Pulmonary Disease

Keywords

  • Asthma
  • Chronic Obstructive pulmonary Disease
  • Pharmacokinetics
  • Healthy volunteers
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and/or female subjects of non- aged 18 to 55 years (inclusive) with suitable veins for cannulation or repeated venipuncture.
  • Females must be non pregnant,non lactating and non-child-bearing potential, confirmed at screening
  • Sexually active male willingness to use
  • (BMI) between 18 and 29.9 kg/m2 inclusive and weigh at least 55 kg and no more than 100 kg inclusive.

Exclusion criteria

Exclusion Criteria:

  • History of any disease, severe allergy/anaphylaxis to any biologic therapy, Guillain-Barré syndrome, smoking and alcohol or drug abuse
  • Diagnosis of helminth parasitic infection and acute upper or lower respiratory infections
  • Disorders related to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment
  • /aspartate aminotransferase level ≥1.5 times the
  • White blood cell count and neutrophils \< lower limit of normal
  • Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of medicinal product (IMP)
  • Positive result for serum surface antigen or anti- C (anti-HBc) antibody, antibody, and (HIV) antibody.
  • Intake of new chemical entity (not been approved for marketing) within 3 months of the first administration of investigational product
  • Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening
  • Receipt of immunoglobulin or blood products within 30 days prior to the date
  • Receipt of any marketed (e.g., omalizumab, mepolizumab etc.) or investigational biologic within 4 months or 5 half-lives prior to the date informed consent
  • Receipt of 30 days prior to randomization on Day 1
  • Current , or history of malignancy except (basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix)
  • Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.
  • Use of antacids, analgesics (except paracetamol/acetaminophen), herbal remedies, mega-dose vitamins (20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer
  • Previous receipt of received benralizumab
  • Any ongoing or recent minor medical complaints
  • Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (actual)

Study arms

  • Active comparator
    Benralizumab by Accessorized Pre-Filled Syringe

    Drug administration by Accessorized Pre-Filled Syringe. A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)

    Biological: Benralizumab

  • Other
    Benralizumab by Autoinjector

    Drug administration by Autoinjector A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)

    Biological: Benralizumab

Interventions

  • BiologicalBenralizumab

    A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.

  • BiologicalBenralizumab

    A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve From Zero to Infinity (AUCinf)

    To compare the AUCinf following single SC administration of Benralizumab by using APFS or AI devices

    Time frame: At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57

  2. Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)

    To compare the AUClast following single SC administration of Benralizumab by using APFS or AI devices

    Time frame: At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57

  3. Maximum Observed Concentration (Cmax)

    To compare the Cmax following single SC administration of Benralizumab by using APFS or AI devices

    Time frame: At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57

Secondary outcomes

  1. Time When Maximum Concentration is Observed (Tmax)

    To evaluate the Tmax of Benralizumab administered to various injection sites and in subjects with different body weight ranges

    Time frame: At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57

  2. Terminal Half-life (t½)

    To evaluate the t½ of Benralizumab administered to various anatomical injection sites and in subjects with different body weight ranges.

    Time frame: At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57

  3. Apparent Extravascular Clearance (CL/F)

    To evaluate the CL/F of Benralizumab administered to various anatomical injection sites and in subjects with different body weight ranges.

    Time frame: At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57

  4. Apparent Volume of Distribution Based on the Terminal Phase (Vz/F)

    To evaluate the Vz/F of Benralizumab administered to various anatomical injection sites and in subjects with different body weight ranges.

    Time frame: At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57

  5. Number of Participants With Adverse Events

    To evaluate safety and tolerability of Benralizumab

    Time frame: At predose and 2 h postdose (Day 1), Days 2, 4, 5, 6, 8, 15, 29, 43 and 57

  6. Antidrug Antibody (ADA) Status

    To evaluate the immunogenicity of Benralizumab

    Time frame: At predose (Day 1), Days 29 and 57

07

Results

Posted Jul 5, 2019

Participant flow

Subjects who met all the inclusion and none of the exclusion criteria were enrolled at PAREXEL Early Phase Clinical Unit in Berlin and London.

Participant flow — Overall Study
MilestoneBenralizumab 30mg Autoinjector (AI)Benralizumab 30mg Accessorized Pre-filled Syringe (AFPS)
Started9090
Completed9090
Not completed00

Outcome measures

PrimaryArea Under the Concentration-time Curve From Zero to Infinity (AUCinf)

To compare the AUCinf following single SC administration of Benralizumab by using APFS or AI devices

Time frame:
At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57
Reported as:
Geometric mean · day·ng/mL
Area Under the Concentration-time Curve From Zero to Infinity (AUCinf)
day·ng/mLBenralizumab 30mg AIBenralizumab 30mg AFPS
Area Under the Concentration-time Curve From Zero to Infinity (AUCinf)72210 ± 29.776220 ± 32.1
Statistical analysis
  • Benralizumab 30mg AI vs Benralizumab 30mg AFPS · ANOVA · Geometric mean ratio (%): 94.46 · 90% CI 88.16 to 101.21
PrimaryArea Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)

To compare the AUClast following single SC administration of Benralizumab by using APFS or AI devices

Time frame:
At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57
Reported as:
Geometric mean · day·ng/mL
Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)
day·ng/mLBenralizumab 30mg AIBenralizumab 30mg AFPS
Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)60560 ± 27.365230 ± 29.2
Statistical analysis
  • Benralizumab 30mg AI vs Benralizumab 30mg AFPS · ANOVA · Geometric mean ratio (%): 92.83 · 90% CI 87.41 to 98.58
PrimaryMaximum Observed Concentration (Cmax)

To compare the Cmax following single SC administration of Benralizumab by using APFS or AI devices

Time frame:
At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration (Cmax)
ng/mLBenralizumab 30mg AIBenralizumab 30mg AFPS
Maximum Observed Concentration (Cmax)2096 ± 32.72269 ± 35.4
Statistical analysis
  • Benralizumab 30mg AI vs Benralizumab 30mg AFPS · ANOVA · Geometric mean ratio (%): 92.34 · 90% CI 86.34 to 98.75
SecondaryTime When Maximum Concentration is Observed (Tmax)

To evaluate the Tmax of Benralizumab administered to various injection sites and in subjects with different body weight ranges

Time frame:
At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57
Reported as:
Median · Days
Time When Maximum Concentration is Observed (Tmax)
DaysBenralizumab 30mg AIBenralizumab 30mg AFPS
Abdomen 55.0 to 69.9 kg4.59 (2.97 to 7.04)6.06 (4.00 to 14.00)
Abdomen 70.0 to 84.9 kg6.98 (3.98 to 14.00)5.98 (2.95 to 14.05)
Abdomen 85.0 to 100.0 kg5.06 (3.95 to 7.11)6.96 (3.99 to 7.10)
Thigh 55.0 to 69.9 kg4.00 (2.97 to 7.01)4.52 (2.94 to 7.04)
Thigh 70.0 to 84.9 kg4.05 (2.98 to 6.90)3.52 (2.95 to 7.12)
Thigh 85.0 to 100.0 kg4.59 (2.94 to 13.95)4.03 (2.98 to 6.98)
Upper arm 55.0 to 69.9 kg6.97 (3.97 to 14.02)4.96 (3.02 to 14.04)
Upper arm 70.0 to 84.9 kg7.00 (5.01 to 14.03)5.02 (2.99 to 8.01)
Upper arm 85.0 to 100.0 kg7.00 (3.09 to 14.03)6.97 (1.02 to 14.13)
SecondaryTerminal Half-life (t½)

To evaluate the t½ of Benralizumab administered to various anatomical injection sites and in subjects with different body weight ranges.

Time frame:
At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57
Reported as:
Geometric mean · Days
Terminal Half-life (t½)
DaysBenralizumab 30mg AIBenralizumab 30mg AFPS
Abdomen 55.0 to 69.9 kg18.83 ± 24.920.15 ± 21.8
Abdomen 70.0 to 84.9 kg20.22 ± 21.017.43 ± 21.7
Abdomen 85.0 to 100.0 kg19.59 ± 19.921.04 ± 21.7
Thigh 55.0 to 69.9 kg18.58 ± 20.619.72 ± 21.4
Thigh 70.0 to 84.9 kg19.93 ± 23.418.28 ± 17.9
Thigh 85.0 to 100.0 kg19.02 ± 19.917.30 ± 11.5
Upper arm 55.0 to 69.9 kg22.46 ± 13.617.30 ± 26.9
Upper arm 70.0 to 84.9 kg20.54 ± 14.020.16 ± 25.3
Upper arm 85.0 to 100.0 kg19.01 ± 26.919.42 ± 26.3
SecondaryApparent Extravascular Clearance (CL/F)

To evaluate the CL/F of Benralizumab administered to various anatomical injection sites and in subjects with different body weight ranges.

Time frame:
At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57
Reported as:
Geometric mean · mL/day
Apparent Extravascular Clearance (CL/F)
mL/dayBenralizumab 30mg AIBenralizumab 30mg AFPS
Abdomen 55.0 to 69.9 kg388.8 ± 34.3388.9 ± 43.8
Abdomen 70.0 to 84.9 kg462.9 ± 29.5508.9 ± 33.2
Abdomen 85.0 to 100.0 kg504.6 ± 18.3402.7 ± 30.4
Thigh 55.0 to 69.9 kg350.1 ± 32.6281.1 ± 16.8
Thigh 70.0 to 84.9 kg393.7 ± 29.6325.9 ± 18.2
Thigh 85.0 to 100.0 kg378.2 ± 26.8406.0 ± 22.9
Upper arm 55.0 to 69.9 kg345.8 ± 24.7455.2 ± 29.8
Upper arm 70.0 to 84.9 kg429.4 ± 19.5366.1 ± 27.0
Upper arm 85.0 to 100.0 kg532.6 ± 21.7471.6 ± 20.3
SecondaryApparent Volume of Distribution Based on the Terminal Phase (Vz/F)

To evaluate the Vz/F of Benralizumab administered to various anatomical injection sites and in subjects with different body weight ranges.

Time frame:
At Pre-dose (Day 1) and at Days 2, 4, 5, 6, 8, 15, 29, 43 and 57
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution Based on the Terminal Phase (Vz/F)
LitersBenralizumab 30mg AIBenralizumab 30mg AFPS
Abdomen 55.0 to 69.9 kg10.56 ± 28.011.30 ± 28.4
Abdomen 70.0 to 84.9 kg13.50 ± 30.412.79 ± 25.5
Abdomen 85.0 to 100.0 kg14.26 ± 25.012.22 ± 15.8
Thigh 55.0 to 69.9 kg9.386 ± 18.27.999 ± 15.5
Thigh 70.0 to 84.9 kg11.32 ± 23.58.596 ± 13.5
Thigh 85.0 to 100.0 kg10.38 ± 20.210.13 ± 21.0
Upper arm 55.0 to 69.9 kg11.21 ± 21.211.36 ± 17.7
Upper arm 70.0 to 84.9 kg12.72 ± 23.610.65 ± 18.7
Upper arm 85.0 to 100.0 kg14.61 ± 23.013.21 ± 32.9
SecondaryNumber of Participants With Adverse Events

To evaluate safety and tolerability of Benralizumab

Time frame:
At predose and 2 h postdose (Day 1), Days 2, 4, 5, 6, 8, 15, 29, 43 and 57
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsBenralizumab 30mg AIBenralizumab 30mg AFPS
Any AE5046
Death00
Any SAE00
Any AE leading to discontinuation00
SecondaryAntidrug Antibody (ADA) Status

To evaluate the immunogenicity of Benralizumab

Time frame:
At predose (Day 1), Days 29 and 57
Reported as:
Count of participants · Participants
Antidrug Antibody (ADA) Status
ParticipantsBenralizumab 30mg AIBenralizumab 30mg AFPS
ADA prevalence (positive at any visit)26
ADA incidence03

Adverse events

Collected over At pre-dose and 2 h post-dose (Day 1), Days 2, 4, 5, 6, 8, 15, 29, 43 and 57. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benralizumab 30mg Autoinjector (AI)0/90 (0%)0/90 (0%)50/90 (55.6%)
Benralizumab 30mg Accessorized Pre-filled Syringe (AFPS)0/90 (0%)0/90 (0%)46/90 (51.1%)
Most frequent other events
Showing 10 of 62
Most frequent other events
EventBenralizumab 30mg Autoinjector (AI)Benralizumab 30mg Accessorized Pre-filled Syringe (AFPS)
NasopharyngitisInfections and infestations18/9013/90
HeadacheNervous system disorders14/905/90
Oropharyngeal painRespiratory, thoracic and mediastinal disorders7/9011/90
CoughRespiratory, thoracic and mediastinal disorders1/905/90
FatigueGeneral disorders5/901/90
ToothacheGastrointestinal disorders4/903/90
VomitingGastrointestinal disorders3/900/90
Back painMusculoskeletal and connective tissue disorders3/901/90
RhinitisInfections and infestations2/900/90
DyspnoeaRespiratory, thoracic and mediastinal disorders0/902/90

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Benralizumab 30mg Autoinjector (AI)Benralizumab 30mg Accessorized Pre-filled Syringe (AFPS)Total
Mean40.8 ± 10.841.1 ± 11.140.9 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Benralizumab 30mg Autoinjector (AI)Benralizumab 30mg Accessorized Pre-filled Syringe (AFPS)Total
Female171633
Male7374147
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Benralizumab 30mg Autoinjector (AI)Benralizumab 30mg Accessorized Pre-filled Syringe (AFPS)Total
Hispanic or Latino123
Not Hispanic or Latino8988177
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Benralizumab 30mg Autoinjector (AI)Benralizumab 30mg Accessorized Pre-filled Syringe (AFPS)Total
American Indian or Alaska Native000
Asian235
Native Hawaiian or Other Pacific Islander000
Black or African American5510
White8380163
More than one race000
Unknown or Not Reported022
08

Study locations

2 sites
  • Research Site
    Berlin, 14050, Germany
  • Research Site
    Harrow, HA1 3UJ, Germany
09

References and documents

Publications

  • Martin UJ, Fuhr R, Forte P, Barker P, Axley MJ, Aurivillius M, Yan L, Roskos L. Comparison of autoinjector with accessorized prefilled syringe for benralizumab pharmacokinetic exposure: AMES trial results. J Asthma. 2021 Jan;58(1):93-101. doi: 10.1080/02770903.2019.1663428. Epub 2019 Sep 20. PubMed 31539289 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Jul 2017, 6 months.

Results were first posted in Jul 2019, 1 year 11 months after primary completion.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 6 months is close to that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2016
First posted
Nov 21, 2016
StartActual
Jan 4, 2017
Primary completionActual
Jul 13, 2017
CompletionActual
Jul 13, 2017
Results first posted
Jul 5, 2019
Last update
Jul 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02968914
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Nov 21, 2016
Start date
Jan 4, 2017
Primary completion
Jul 13, 2017
Completion
Jul 13, 2017
Results posted
Jul 5, 2019
Last update
Jul 5, 2019

Study contacts

Dr. Rainard Fuhr, Medicine
principal investigator · PAREXEL Early Phase Clinical Unit Berlin
Dr. Pablo Forte-Soto
principal investigator · PAREXEL Early Phase Clinical Unit London

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion